AKT1 and meningioma: Similarly, considerable activation of mutated AKTs in the PI3K/AKT/mTOR pathway is also reported in some meningiomas, and trials of inhibitors of these pathways (capivasertib, alpesilib, vistusertib) are also ongoing [61,62,63].